Product nameAnti-Vitronectin/S-Protein antibody [EP873Y] (HRP)
See all Vitronectin/S-Protein primary antibodies
DescriptionRabbit monoclonal [EP873Y] to Vitronectin/S-Protein (HRP)
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
corresponding to Human Vitronectin/S-Protein aa 450 to the C-terminus. Synthetic peptide corresponding to residues near the V10 subunit of human Vitronectin.
- WB: Human serum. IHC-P: Normal human liver tissue.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. Store In the Dark.
Storage bufferpH: 7.4
Preservative: 0.1% Proclin
Constituents: PBS, 30% Glycerol, 1% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab199310 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000. Detects a band of approximately 75 kDa.|
|IHC-P||1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ab199507 - Rabbit monoclonal IgG (HRP), is suitable for use an as isotype control with this antibody.
FunctionVitronectin is a cell adhesion and spreading factor found in serum and tissues. Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway.
Somatomedin-B is a growth hormone-dependent serum factor with protease-inhibiting activity.
Sequence similaritiesContains 4 hemopexin repeats.
Contains 1 SMB (somatomedin-B) domain.
DomainThe SMB domain mediates interaction with SERPINE1/PAI1. The heparin-binding domain mediates interaction with insulin.
modificationsSulfated on 2 tyrosine residues.
N- and O-glycosylated.
Phosphorylation on Thr-69 and Thr-76 favors cell adhesion and spreading.
It has been suggested that the active SMB domain may be permitted considerable disulfide bond heterogeneity or variability, thus two alternate disulfide patterns based on 3D structures are described with 1 disulfide bond conserved in both.
Phosphorylation sites are present in the extracellular medium.
Cellular localizationSecreted, extracellular space.
- Information by UniProt
- Complement S Protein antibody
- Epibolin antibody
- S Protein antibody
Anti-Vitronectin/S-Protein antibody [EP873Y] (HRP) (ab199310) at 1/5000 dilution + Human Serum Tissue Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Observed band size: 74 kDa why is the actual band size different from the predicted?
Exposure time: 2 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab199310 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
IHC image of Vitronectin/S-Protein staining in a section of formalin-fixed paraffin-embedded normal human liver*, performed on a Leica BOND. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab199310 at 1/100 dilution for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre.
ab199310 has not yet been referenced specifically in any publications.